SEC Form 4 · accession 0001127602-17-031273
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregg H Alton
Officer — EVP Comm&Acs ALA, Corp&Med Aff
Period of report
Nov 1, 2017
Accepted (ET)
Nov 3, 2017 · 6:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 1, 2017 | M | 8,625 | $24.905 | A | 77,363 | D | |
| Common StockF3 | Nov 1, 2017 | S | 13,400 | $74.7397 | D | 63,963 | D | |
| Common StockF4 | Nov 1, 2017 | S | 1,600 | $75.4831 | D | 62,363 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $24.905 | Nov 1, 2017 | M | 8,625 | D | — | Jul 29, 2019 | Common Stock | 8,625 | 24,751 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $74.22 to $75.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $75.25 to $75.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.